Education
About Us
Working with TipRanks
Follow Us
Biophytis SA (FR:ALBPS)
:ALBPS
Top Page
Biophytis SA
(ALBPS)
Select Model
Select Model
Rating:40Underperform
Price Target:
€0.06
▼(-1.67% Downside)
The score is driven primarily by weak financial fundamentals (no revenue, ongoing losses, negative equity and funding risk), reinforced by bearish technicals (price below key moving averages and negative MACD). Oversold indicators (low RSI/Stoch) provide limited support without confirmation, and valuation is constrained by negative earnings and no dividend data.
Biophytis SA (ALBPS) vs. iShares MSCI France ETF (EWQ)
Market Cap
€2.69M
Dividend YieldN/A
Average Volume (3M)346.06K
Price to Earnings (P/E)―
Beta (1Y)0.40
Revenue GrowthN/A
EPS GrowthN/A
CountryFR
Employees22
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.18
Shares Outstanding42,118,282
10 Day Avg. Volume335,651
30 Day Avg. Volume346,065
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.20
Price to Sales (P/S)0.00
P/FCF Ratio-0.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Biophytis SA Business Overview & Revenue Model
Company DescriptionBiophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.
How the Company Makes Money
Biophytis SA Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -357.00K | -298.00K | -803.00K | -484.00K | -311.00K | -280.00K |
| EBITDA | -6.82M | -8.26M | -13.80M | -25.52M | -26.50M | -13.66M |
| Net Income | -8.03M | -10.38M | -17.03M | -24.22M | -31.16M | -25.52M |
Balance Sheet | ||||||
| Total Assets | 6.62M | 6.90M | 11.96M | 21.99M | 36.26M | 27.21M |
| Cash, Cash Equivalents and Short-Term Investments | 1.21M | 78.00K | 5.57M | 11.05M | 25.16M | 18.35M |
| Total Debt | 7.77M | 9.84M | 8.27M | 14.58M | 17.55M | 9.10M |
| Total Liabilities | 14.44M | 16.60M | 15.85M | 23.90M | 30.56M | 20.38M |
| Stockholders Equity | -7.78M | -9.67M | -3.86M | -1.88M | 5.83M | 2.30M |
Cash Flow | ||||||
| Free Cash Flow | -2.68K | -8.64M | -13.09M | -19.13M | -24.14M | -10.08M |
| Operating Cash Flow | -3.69M | -8.64M | -12.87M | -18.99M | -23.80M | -9.86M |
| Investing Cash Flow | 19.00K | 10.00K | 370.00K | -17.00K | 12.16M | -12.71M |
| Financing Cash Flow | 5.34M | 3.14M | 7.03M | 6.13M | 29.71M | 21.95M |
Biophytis SA Peers Comparison
UnderperformOutperform
Sector (51)
FR:ALBPS
Biophytis SA
0.06
-0.20
-76.14%
DE:0N6A
TME Pharma N.V.
0.06
-0.01
-14.49%
DE:3VG
Theranexus SA
2.08
1.54
285.19%
DE:0LW0
Neovacs SA
0.01
-979.99
-100.00%
FR:ALINT
IntegraGen SA
0.14
-0.71
-84.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.